Most of the patients who responded to zolpidem for noninsomnia neurological disorders had either a disorder of consciousness or a movement disorder, Bomalaski reports. That includes those in comas and vegetative states, and others with Parkinson’s disease and dystonia. In addition, some other patients who had experienced a stroke or traumatic brain injury, or patients with dementia, were prescribed for a range of symptoms, including aphasia, apathy and motor coordination. In all, more than 20 neurological disorders were part of the review.
Significant but transient effects
Original Research: Abstract for “Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review” by Martin N. Bomalaski, MD; Edward S. Claflin, MD; Whitney Townsend, MLIS; and Mark D. Peterson, PhD, MS in JAMA Neurology. Published online June 26 2017 doi:10.1001/jamaneurol.2017.1133